Cytochroma secures $12-million private financing

Guest Contributor
November 13, 2001

Kingston ON-based Cytochroma Inc has closed a $12-million private equity financing to advance its R&D of therapeutics based on cytochrome P450-based metabolism. The Business Development Bank of Canada’s Venture Capital Division is the lead investor, with participation from Novo A/S (Denmark), GeneChem Technologies Venture Fund LP, Canadian Medical Discoveries Fund and Working Ventures Canadian Fund Inc. Cytochroma has already entered into collab- oration with Allergan Inc and is seeking new partnerships as it expands its pipeline of gene targets and drug candidates….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.